New eczema drug shows promise in early trial
NCT ID NCT03822832
First seen Nov 01, 2025
Summary
This Phase 2 trial tested a drug called spesolimab (BI 655130) in 51 adults with moderate to severe atopic dermatitis (eczema). Participants received either the drug or a placebo intravenously. The study measured how much eczema severity changed over 16 weeks using the EASI score, and also tracked side effects. The goal was to see if the drug is safe and effective for treating this chronic skin condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DERMATITIS, ATOPIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aichi Medical University Hospital
Aichi, Nagakute, 480-1195, Japan
-
Center for Clinical Studies
Webster, Texas, 77598, United States
-
Center for Dermatology and Plastic Surgery
Scottsdale, Arizona, 85260, United States
-
Clinical Physiology Associates
Fort Myers, Florida, 33912, United States
-
Dermatology Treatment and Research Center, PA
Dallas, Texas, 75230, United States
-
Finlay Medical Research Corp
Miami, Florida, 33126, United States
-
ForCare Clinical Research, Inc.
Tampa, Florida, 33613, United States
-
Hosui General Medical Clinic
Hokkaido, Sapporo, 064-0807, Japan
-
Innovaderm Research Inc.
Montreal, Quebec, H2X 2V1, Canada
-
Kurume University Hospital
Fukuoka, Kurume, 830-0011, Japan
-
Nagasaki University Hospital
Nagasaki, Nagasaki, 852-8501, Japan
-
National Hospital Organization Kyushu Medical Center
Fukuoka, Fukuoka, 810-8563, Japan
-
NewLab Clinical Research Inc.
St. John's, Newfoundland and Labrador, A1C 2H5, Canada
-
Osaka City University Hospital
Osaka, Osaka, 545- 8586, Japan
-
Progressive Clinical Research
San Antonio, Texas, 78213, United States
-
Showa University Hospital
Tokyo, Shinagawa-ku, 142-8666, Japan
-
Tennocho Ekimae Dermatology and Allergology
Kanagawa, Yokohama, 240-0004, Japan
-
The Indiana Clinical Trials Center, PC
Plainfield, Indiana, 46168, United States
-
Tokyo Medical University Hachioji Medical Center
Tokyo, Hachioji, 193-0998, Japan
-
Unity Clinical Research
Oklahoma City, Oklahoma, 73118, United States
-
University Hospital Kyoto Prefectural University of Medicine
Kyoto, Kyoto, 602-8566, Japan
-
University of Alberta Hospital (University of Alberta)
Edmonton, Alberta, T6G 2B7, Canada
-
University of South Florida
Tampa, Florida, 33612, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Spesolimab (BI 655130)
What this could lead to
If successful, this could lead to a new treatment option for people with moderate to severe atopic dermatitis that is not well controlled by current therapies.
What could go wrong
This is an early Phase 2 trial with only 51 participants, so results may not apply to everyone. The drug may not prove effective or could have side effects not yet seen.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.